SAN DIEGO & BOSTON & BILBAO, Spain--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic…
Agreement establishes framework for advancing Mass General Brigham-originated cell and gene therapies. Landmark Bio to support early-stage development and manufacturing through collaboration with Mass General Brigham’s Gene and Cell Therapy Institute.
Acquisition enables Landmark Bio to scale capabilities to accelerate development and manufacturing of advanced therapies. Artis BioSolutions to provide strategic investment to build technology and operations. Company to continue operating independently, leveraging position in Massachusetts’ life sciences ecosystem
Grant allows ChromaTan and Landmark Bio to create a scalable, cost-effective, and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors. Project developed with award from NIIMBL and financial assistance from the National Institute of Standards and Technology.
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos’ CAR-T product candidates in the Boston area
Landmark Bio will serve as strategic partner in the development and manufacturing of InnDura’s pipeline products
New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusetts, offers end-to-end capabilities and onestop manufacturing solutions
Newest members of Landmark Bio’s executive team bring decades of industry leadership and expertise in drug development and biomanufacturing